{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:14:14Z","timestamp":1793751254765,"version":"4.6.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Anti-sclerostin antibodies are novel biologics for the treatment of postmenopausal osteoporosis, while their efficacy and safety are yet to be fully understood. The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of anti-sclerostin antibodies compared to placebo, alendronate, teriparatide and denosumab in the treatment of osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis included a total of 10 randomized controlled trials (RCTs),involving 12,384 participants with postmenopausal osteoporosis, comparing anti-sclerostin antibodies with alendronate, teriparatide, denosumab, or placebo in postmenopausal women with osteoporosis. The quality of randomized controlled trials was evaluated by using the Cochrane Collaboration\u2019s Randomized Controlled Trial Risk of Bias Assessment Tool, and meta-analysis was performed by using the RevMan software. The primary outcome was the percentage change in bone mineral density(BMD)at 6 and 12 months compared to baseline. Secondary outcomes included the incidence of adverse events and cardiovascular complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with placebo, alendronate, and teriparatide, anti-sclerostin antibodies significantly increased BMD at the lumbar spine, total hip, and femoral neck at 6 and 12 months. Compared with denosumab, anti-sclerostin antibodies significantly increased lumbar spine bone mineral density at 6 months (MD = 3.68, 95% CI: 0.34-7.01, P = 0.03) and 12 months (MD = 5.20, 95% CI: 3.19\u20137.21, P &amp;lt; 0.00001). No significant differences in BMD were found at the total hip and femoral neck versus denosumab. Regarding safety, anti-sclerostin antibodies had a lower incidence of adverse events than alendronate (RR = 0.96, 95% CI: 0.93\u20130.99, P = 0.02) but a higher incidence than teriparatide (RR = 1.13, 95% CI: 1.01\u20131.25, P = 0.03). There was no significant difference in adverse events compared to placebo (RR = 0.98, 95% CI: 0.96\u20131, P = 0.1) or denosumab (RR = 2.64, 95% CI: 0.74\u20139.36, P = 0.13). Importantly, anti-sclerostin antibodies did not significantly increase the risk of cardiovascular complications compared to other treatments (RR = 1.23, 95% CI: 0.92\u20131.64, P = 0.17).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-sclerostin antibodies are effective at increasing BMD, with a pronounced effect on the lumbar spine, and demonstrate a controllable overall risk profile. The study results demonstrate that anti-sclerostin antibodies can be used to treat postmenopausal osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/recorddashboard<\/jats:ext-link>\n                      , identifier CRD420251103597.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1732708","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:12Z","timestamp":1768800492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Lianzhi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Rheumatism and Immunology, Peking University Shenzhen Hospital","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Key Laboratory of Inflammatory and Immunologic Diseases","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology, Peking University Shenzhen Hospital","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Key Laboratory of Inflammatory and Immunologic Diseases","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Rheumatism and Immunology, Peking University Shenzhen Hospital","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Key Laboratory of Inflammatory and Immunologic Diseases","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5594","article-title":"Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials (CDM-J)","volume":"32","author":"Huang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae028","article-title":"3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate","volume":"39","author":"Lewiecki","year":"2024","journal-title":"J Bone Miner Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","article-title":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"129","author":"Hernandez","year":"2019","journal-title":"Maturitas"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"Bmj"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.3390\/ijms242115772","article-title":"Molecular and cellular mechanisms of osteoporosis","volume":"24","author":"Zhivodernikov","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","article-title":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study","volume":"162","author":"Kobayakawa","year":"2022","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2021.11.005","article-title":"Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review","volume":"25","author":"Poutoglidou","year":"2022","journal-title":"J Clin Densitom"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06544-2","article-title":"Romosozumab efficacy and safety in European patients enrolled in the FRAME trial","volume":"33","author":"Langdahl","year":"2022","journal-title":"Osteoporos Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05324-0","article-title":"randomized ARCH study","volume":"31","author":"Lau","year":"2020","journal-title":"Osteoporos Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-998","article-title":"Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis","volume":"11","author":"Su","year":"2022","journal-title":"Ann Palliat Med"},{"key":"B13","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.848","article-title":"Romosozumab in postmenopausal korean women with osteoporosis: A randomized, double-blind, placebo-controlled efficacy and safety study","volume":"36","author":"Baek","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac059","article-title":"Comparison of romosozumab versus denosumab treatment on bone mineral density after 1\u2009year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study","volume":"33","author":"Mochizuki","year":"2023","journal-title":"Mod Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2021.08.001","article-title":"Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study","volume":"7","author":"Mochizuki","year":"2021","journal-title":"Osteoporos Sarcopenia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"22441","DOI":"10.1038\/s41598-025-05187-7","article-title":"A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis","volume":"15","author":"Sobue","year":"2025","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/jmh.jmh_108_25","article-title":"Comparison of efficacy and safety of romosozumab versus denosumab for treatment of postmenopausal osteoporosis: A meta-analysis","volume":"16","author":"Singh","year":"2025","journal-title":"J Midlife Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e935491","DOI":"10.12659\/MSM.935491","article-title":"Pharmacological therapies for osteoporosis: A bayesian network meta-analysis","volume":"28","author":"Shen","year":"2022","journal-title":"Med Sci Monit"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.19.01008","article-title":"Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: A randomized phase-2 study","volume":"102","author":"Bhandari","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"B28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-019-01057-1","article-title":"Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial","volume":"38","author":"Takada","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1188969","article-title":"Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","author":"Keaveny","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/os.13136","article-title":"Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis through a Grade Analysis of Evidence","volume":"13","author":"Tian","year":"2021","journal-title":"Orthop Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","article-title":"Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"48","author":"Cheng","year":"2025","journal-title":"Drug Saf"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.317635","article-title":"Role of sclerostin in cardiovascular disease","volume":"42","author":"Golledge","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn","year":"2020","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1851192","article-title":"Pharmacological management of postmenopausal osteoporosis: a level I evidence based - expert opinion","volume":"14","author":"Migliorini","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: A propensity-score-matched cohort study","volume":"110","author":"Stokar","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae484","article-title":"The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis","volume":"110","author":"Hartz","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1732708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:35:50Z","timestamp":1771918550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1732708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":42,"alternative-id":["10.3389\/fendo.2025.1732708"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1732708","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1732708"}}